Huangkui capsule mitigates diabetic nephropathy via epigenetic therapy effects
This study provides the first evidence that HKC ameliorates DN through epigenetic therapy effects, specifically by restoring DNA methylation and transcriptional activity of renal target genes. Further biological experiments to validate these findings are necessary.
Authors
- Yihong Yu
- Haitao Ge
- Nan Li
- Jie Wu
- Harvest F. Gu
- Haitao Tang
Institutions
- Medigene (Germany) (DE)
- Nanjing University of Chinese Medicine (CN)
- Qilu University of Technology (CN)
- China Pharmaceutical University (CN)
- Jiangsu Province Hospital (CN)
- Taizhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.3389/fphar.2026.1775173
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China